Dr Reddy's Laboratories Ltd's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 51/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 14.94.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dr Reddy's Laboratories Ltd's Score
Industry at a Glance
Industry Ranking
51 / 158
Overall Ranking
130 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Hold
Current Rating
14.943
Target Price
+7.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Dr Reddy's Laboratories Ltd Highlights
StrengthsRisks
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25.74% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.85B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 11.81%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 11.81%.
Undervalued
The company’s latest PE is 17.30, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 112.51M shares, decreasing 12.37% quarter-over-quarter.
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Ticker SymbolRDY
CompanyDr Reddy's Laboratories Ltd
CEOAghanian (Patrick)
Websitehttps://www.drreddys.com/
FAQs
What is the current price of Dr Reddy's Laboratories Ltd (RDY)?
The current price of Dr Reddy's Laboratories Ltd (RDY) is 14.200.
What is the symbol of Dr Reddy's Laboratories Ltd?
The ticker symbol of Dr Reddy's Laboratories Ltd is RDY.
What is the 52-week high of Dr Reddy's Laboratories Ltd?
The 52-week high of Dr Reddy's Laboratories Ltd is 16.170.
What is the 52-week low of Dr Reddy's Laboratories Ltd?
The 52-week low of Dr Reddy's Laboratories Ltd is 12.260.
What is the market capitalization of Dr Reddy's Laboratories Ltd?
The market capitalization of Dr Reddy's Laboratories Ltd is 11.82B.
What is the net income of Dr Reddy's Laboratories Ltd?
The net income of Dr Reddy's Laboratories Ltd is 668.95M.
Is Dr Reddy's Laboratories Ltd (RDY) currently rated as Buy, Hold, or Sell?
According to analysts, Dr Reddy's Laboratories Ltd (RDY) has an overall rating of Hold, with a price target of 14.943.
What is the Earnings Per Share (EPS TTM) of Dr Reddy's Laboratories Ltd (RDY)?
The Earnings Per Share (EPS TTM) of Dr Reddy's Laboratories Ltd (RDY) is 0.820.